News & Updates

Obese breast cancer patients on T-DM1 prone to more treatment adjustments
Obese breast cancer patients on T-DM1 prone to more treatment adjustments
04 Feb 2022

More treatment modifications secondary to adverse events appear necessary among obese patients receiving ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer, relative to nonobese counterparts, reports a study.

Obese breast cancer patients on T-DM1 prone to more treatment adjustments
04 Feb 2022
Systemic inflammation mediates obesity-related severe COVID-19
Systemic inflammation mediates obesity-related severe COVID-19
04 Feb 2022 byStephen Padilla

Systemic inflammation plays a significant role in severe COVID-19 associated with obesity, particularly in patients aged <65 years, as captured by peak C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR), a study has found.

Systemic inflammation mediates obesity-related severe COVID-19
04 Feb 2022